XL092 is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values in cell-based assays of 15, 1.6, 3.4, and 7.2 nM respectively. In xenograft studies, XL092 caused substantial tumor growth inhibition following 10 mg/kg daily oral dosing for 14 days. XL092 has good oral bioavailability and a significantly shorter half-life than cabozantinib.
仅供研究使用。 我们不向患者出售。
名称 | XL092 |
---|---|
Iupac 化学名称 | 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]- |
同义词 | JUN04542; JUN-04542; JUN 04542; XL092; XL-092; X L092; Zanzalintinib |
英文同义词 | JUN04542; JUN-04542; JUN 04542; XL092; XL-092; X L092; Zanzalintinib |
分子式 | C29H25FN4O5 |
分子量 | 528.53 |
Smile | O=C(C1(C(NC2=CC=C(OC3=CC=NC4=CC(OC)=C(C(NC)=O)C=C34)C=C2)=O)CC1)NC5=CC=C(F)C=C5 |
InChiKey | JSPCKALGNNVYOO-UHFFFAOYSA-N |
InChi | InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37) |
Cas号 | 2367004-54-2 |
相关CAS号 |
包装 | 价格 | 库存 | 纯度 | 备货期 |
---|---|---|---|---|
大货 | 询价 | 询价 | 询价 |